330 related articles for article (PubMed ID: 30851640)
1. Alemtuzumab as rescue therapy in case of multiple sclerosis rebound following Natalizumab break: Clinical case and literature review.
Federle L; Puthenparampil M; Stenta G; Paolo G; Francesco P
Mult Scler Relat Disord; 2019 May; 30():262-264. PubMed ID: 30851640
[TBL] [Abstract][Full Text] [Related]
2. Severe CNS inflammation after discontinuation of natalizumab and start of daclizumab successfully treated with alemtuzumab.
Hümmert MW; Deppe J; Pul R; Wurster U; Schwenkenbecher P; Sühs KW; Bronzlik P; Stangel M; Skripuletz T
Mult Scler Relat Disord; 2018 May; 22():87-89. PubMed ID: 29631243
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of alemtuzumab and natalizumab for relapsing-remitting multiple sclerosis treatment in Iran: decision analysis based on an indirect comparison.
Taheri S; Sahraian MA; Yousefi N
J Med Econ; 2019 Jan; 22(1):71-84. PubMed ID: 30380350
[TBL] [Abstract][Full Text] [Related]
4. Rescue therapy with alemtuzumab in multiple sclerosis post-natalizumab puerperium reactivation.
Frau J; Coghe G; Fenu G; Lorefice L; Cocco E
Neurol Sci; 2018 Feb; 39(2):389-390. PubMed ID: 28986705
[No Abstract] [Full Text] [Related]
5. Cost-Effectiveness of Alemtuzumab in the Treatment of Relapsing Forms of Multiple Sclerosis in the United States.
Chirikov V; Ma I; Joshi N; Patel D; Smith A; Giambrone C; Cornelio N; Hashemi L
Value Health; 2019 Feb; 22(2):168-176. PubMed ID: 30711061
[TBL] [Abstract][Full Text] [Related]
6. Disease reactivation after switching from natalizumab to daclizumab.
Uphaus T; Oberwittler C; Groppa S; Zipp F; Bittner S
J Neurol; 2017 Dec; 264(12):2491-2494. PubMed ID: 28975400
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of alemtuzumab and natalizumab in the treatment of different stages of multiple sclerosis patients.
Wang L; Qi CH; Zhong R; Yuan C; Zhong QY
Medicine (Baltimore); 2018 Feb; 97(8):e9908. PubMed ID: 29465579
[TBL] [Abstract][Full Text] [Related]
8. Alemtuzumab as rescue therapy in a cohort of 50 relapsing-remitting MS patients with breakthrough disease on fingolimod: a multi-center observational study.
Huhn K; Bayas A; Doerck S; Frank B; Gerbershagen K; Hellwig K; Kallmann B; Kleinschnitz C; Kleiter I; Lee DH; Limmroth V; Mäurer M; Meuth S; Rieckmann P; Ruck T; Gold R; Linker RA
J Neurol; 2018 Jul; 265(7):1521-1527. PubMed ID: 29696498
[TBL] [Abstract][Full Text] [Related]
9. Treating MS after surviving PML: Discrete strategies for rescue, remission, and recovery patient 2: From the National Multiple Sclerosis Society Case Conference Proceedings.
Cruz RA; Hogan N; Sconzert J; Sconzert M; Major EO; Lisak RP; Melamed E; Varkey TC; Meltzer E; Goodman A; Komogortsev O; Parsons MS; Costello K; Graves JS; Newsome S; Zamvil SS; Frohman EM; Frohman TC
Neurol Neuroimmunol Neuroinflamm; 2021 Jan; 8(1):. PubMed ID: 33434885
[No Abstract] [Full Text] [Related]
10. Switching from natalizumab to alemtuzumab in patients with relapsing multiple sclerosis.
John N; Carroll A; Brownlee WJ; Chataway J
J Neurol Neurosurg Psychiatry; 2019 Dec; 90(12):1376-1378. PubMed ID: 31079064
[No Abstract] [Full Text] [Related]
11. Cost-effectiveness of cladribine tablets, alemtuzumab, and natalizumab in the treatment of relapsing-remitting multiple sclerosis with high disease activity in England.
Hettle R; Harty G; Wong SL
J Med Econ; 2018 Jul; 21(7):676-686. PubMed ID: 29618273
[TBL] [Abstract][Full Text] [Related]
12. Update on monitoring and adverse effects of approved second-generation disease-modifying therapies in relapsing forms of multiple sclerosis.
Dubey D; Cano CA; Stüve O
Curr Opin Neurol; 2016 Jun; 29(3):278-85. PubMed ID: 27027553
[TBL] [Abstract][Full Text] [Related]
13. Clinical and radiologic rebound after discontinuation of natalizumab therapy in a highly active multiple sclerosis patient was not halted by dimethyl-fumarate: a case report.
Patti F; Leone C; Zappia M
BMC Neurol; 2015 Dec; 15():252. PubMed ID: 26643473
[TBL] [Abstract][Full Text] [Related]
14. A multicenter, non-interventional study to evaluate the disease activity in Multiple Sclerosis after withdrawal of Natalizumab in Portugal.
Ladeira F; Braz L; Salgado P; Vaz S; Leitão L; Félix C; Correia AS; Silva AMD; Salgado V; Ferreira F; Vale J; Sá MJ; Capela C
Clin Neurol Neurosurg; 2019 Sep; 184():105390. PubMed ID: 31306895
[TBL] [Abstract][Full Text] [Related]
15. Long-term remission of tumefactive relapsing multiple sclerosis after alemtuzumab rescue treatment in an adolescent patient.
Baroncini D; Annovazzi P; Guaschino C; Minonzio G; Hametner S; Stadelmann C; Comi G; Ghezzi A; Zaffaroni M
Mult Scler Relat Disord; 2020 Jun; 41():102061. PubMed ID: 32203930
[No Abstract] [Full Text] [Related]
16. Escalation Versus Induction/High-Efficacy Treatment Strategies for Relapsing Multiple Sclerosis: Which is Best for Patients?
Edan G; Le Page E
Drugs; 2023 Oct; 83(15):1351-1363. PubMed ID: 37725259
[TBL] [Abstract][Full Text] [Related]
17. Prevention of rebound effect after natalizumab withdrawal in multiple sclerosis. Study of two high-dose methylprednisolone schedules.
Fuentes-Rumí L; Hernández-Clares R; Carreón-Guarnizo E; Valero-López G; Iniesta-Martinez F; Cabrera-Maqueda JM; León-Hernández A; Zamarro-Parra J; Morales-Ortiz A; Meca-Lallana JE
Mult Scler Relat Disord; 2020 Sep; 44():102311. PubMed ID: 32593958
[TBL] [Abstract][Full Text] [Related]
18. Natalizumab treatment during pregnancy in multiple sclerosis-clinical and bioethical aspects of an ongoing debate.
Berek K; Paganini C; Hegen H; Bsteh G; Grams A; Auer M; Berger T; Deisenhammer F; Di Pauli F
Wien Med Wochenschr; 2022 Nov; 172(15-16):373-378. PubMed ID: 35142953
[TBL] [Abstract][Full Text] [Related]
19. Catastrophic outcome of patients with a rebound after Natalizumab treatment discontinuation.
González-Suarez I; Rodríguez de Antonio L; Orviz A; Moreno-García S; Valle-Arcos MD; Matias-Guiu JA; Valencia C; Jorquera Moya M; Oreja-Guevara C
Brain Behav; 2017 Apr; 7(4):e00671. PubMed ID: 28413713
[TBL] [Abstract][Full Text] [Related]
20. Is there a change of paradigm towards more effective treatment early in the course of apparent high-risk MS?
Fernández Ó
Mult Scler Relat Disord; 2017 Oct; 17():75-83. PubMed ID: 29055479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
